Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Co Sertraline · DIN 02287404 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2007-04-02 Health Canada: Cancelled post market since 2018-07-09 · brand ACT SERTRALINE · ATC N06AB06 SERTRALINE · form Capsule · route Oral · ingredients SERTRALINE (SERTRALINE HYDROCHLORIDE) 50 MG · company Actavis pharma company · schedule Prescription

DIN 02287404: Co Sertraline Raw flags: sec3=Y Item: 281604060; group id 470; item number 1182; lccId None; manufacturer id COB Source form: Cap; strength: 50mg Recorded listing: General benefit Source prices (unrounded): $0.3032; ministry $0.3032 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287404 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77281

Interchangeable products

AG-Sertraline · DIN 02477890 · $0.3032 Apo-Sertraline · DIN 02238281 · $0.3032 Auro-Sertraline · DIN 02390914 · $0.3032 Jamp-Sertraline · DIN 02357151 · $0.3032 M-Sertraline · DIN 02530945 · $0.3032 Mar-Sertraline · DIN 02399423 · $0.3032 Mint-Sertraline · DIN 02402394 · $0.3032 NRA-Sertraline · DIN 02488442 · $0.3032 PMS-Sertraline · DIN 02244839 · $0.3032 Sandoz Sertraline · DIN 02245160 · $0.3032 Sertraline · DIN 02353539 · $0.3032 Sertraline · DIN 02386089 · $0.3032 Sertraline · DIN 02469634 · $0.3032 Teva-Sertraline · DIN 02240484 · $0.3032 Zoloft · DIN 01962817 · $0.3032

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287404

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Cancelled post market since 2018-07-09 — choose a marketed DIN from the same-category list.